trial · primary record
Amivantamab
Non-Small-Cell Lung Cancer
| Phase | Phase 1 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 751 |
| Primary completion | 2027-12-31 |
| Primary endpoint | Part 1: Number of Participants With Dose Limiting Toxicity (DLT) |
| Registry ID | NCT02609776 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:29.196Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02609776
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Amivantamab · compound